What's new

EMEA-002362-PIP02-19-M03

EMEA-002362-PIP02-19-M03

Jun 11, 2025 - 16:25
 0
EMEA-002362-PIP02-19-M03
EMEA-002362-PIP02-19-M03
Read More

Tags:

Previous Article

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib...

Next Article

EMEA-001823-PIP01-15-M03

Related Posts

EMEA-003248-PIP02-23

EMEA-003248-PIP02-23

Jun 10, 2025  0

Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - October 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 October 2025, 11:00 (CEST) to 14 October 2025, 12:00 (CEST)

Questions and answers clinic on Product Management Serv...

May 15, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0102/2024

Opinion/decision on a Paediatric investigation plan (PI...

Jun 6, 2025  0